Holen Sie sich die Stockscreener-App
125.99
2.23%
-2.87
Handel nachbörslich:
126.04
0.05
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$128.86
Offen:
$128.34
24-Stunden-Volumen:
7.86M
Relative Volume:
0.77
Marktkapitalisierung:
$311.17B
Einnahmen:
$65.51B
Nettoeinkommen (Verlust:
$8.93B
KGV:
35.46
EPS:
3.5532
Netto-Cashflow:
$14.12B
1W Leistung:
+0.49%
1M Leistung:
+5.41%
6M Leistung:
+13.51%
1J Leistung:
+54.84%
1-Tages-Spanne:
$125.14
$128.99
1-Wochen-Bereich:
$125.14
$130.00
52-Wochen-Spanne:
$76.66
$130.29
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
125.99 | 318.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,215.83 | 1.10T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 643.30B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
252.74 | 449.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
155.17 | 299.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-02-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-10-13 | Fortgesetzt | Citigroup | Neutral |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Merck & Co. highlights oncology pipeline progress as S&P 500 healthcare heavyweight. Longer-term gro - AD HOC NEWS
Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds - IPO Edge
Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Merck & Co. focuses on oncology pipeline as investors watch long-term growth - AD HOC NEWS
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? - The Motley Fool
Merck & Co. Inc. balances pharmaceuticals growth and pipeline investment - AD HOC NEWS
Merck & Co. highlights its pharmaceutical portfolio as investors track long-term growth prospects - AD HOC NEWS
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Merck & Co. highlights its pharmaceuticals strength as investors track long term growth - AD HOC NEWS
Merck & Co. highlights its pharmaceutical portfolio as a major global healthcare player - AD HOC NEWS
Merck & Co. looks to long-term growth as a global pharmaceutical leader - AD HOC NEWS
Merck & Co. Inc. stock underperforms Monday when compared to competitors - MarketWatch
Merck & Co. focuses on oncology and vaccines as investors watch long-term growth - AD HOC NEWS
HSBC Adjusts Price Target on Merck & Co to $150 From $135 - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on Merck to $145 From $140 - Moomoo
Merck & Company, Inc. (MRK): Investor Outlook with a 2.62% Dividend Yield and Robust Buy Ratings - DirectorsTalk Interviews
MRK Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Merck & Co., Inc. – BX:6MK - TradingView
Redwood Grove Capital, LLC's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co Inc (MRK) Shares Surge 3.3% -- What GF Score of 78 Te - GuruFocus
Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Merck & Co Inc Stock (MRK) Closed Up by 3.16% on Jul 2: What Signal Does It Send? - TradingKey
Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up (NYSE:MRK) - Seeking Alpha
MRKMerck & Co Inc Volatility & Greeks - Finviz
Merck & Co. focuses on long-term growth as a global healthcare leader - AD HOC NEWS
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - BioSpace
Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says - Moomoo
Merck & Co earnings guidance frames 2026 outlook. Technicals show MRK trading in a tight range - AD HOC NEWS
Merck, AbbVie probed by US lawmakers over China clinical trials: report - Proactive financial news
Merck & Co. dividend track and pharma pipeline, shares in a mature Dow component - AD HOC NEWS
Merck (NYSE:MRK) Draws Heat As Healthcare Surges - Kalkine Media
Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh - TradingView
Merck expands HIV drug access through state AIDS programs - Stock Titan
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Business Wire
Merck & Company, Inc. (MRK) Stock Analysis: Evaluating Growth Prospects Amid a 1.35% Potential Upside - DirectorsTalk Interviews
Merck & Co. highlights Keytruda momentum, pharma stock in long-term focus - AD HOC NEWS
The Keytruda from Merck & Co. Inc.lung cancer data extend its reach - AD HOC NEWS
Merck & Co., Inc.(NYSE: MRK) added to Russell 1000 Dynamic Index - marketscreener.com
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRK - The National Law Review
Merck & Co. updates on Keytruda data, shares anchored by strong oncology franchise - Ad-hoc-news.de
Merck & Co. opens the week with earnings focus, shares in New York - Ad-hoc-news.de
Lost Money on Merck & Co., Inc. (MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - The National Law Review
Merck & Co., Inc. Actuals & Estimates (FWB:6MK) - TradingView
Merck & Co. highlights oncology pipeline, shares supported by long-term drug portfolio - Ad-hoc-news.de
Merck & Co, shares trade near Wall Street consensus - AD HOC NEWS
Merck & Co. Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Merck & Co., Inc. Actuals & Estimates (AQUISEU:6MKD) - TradingView
Merck & Co. sets Keytruda growth expectations, shares supported by oncology pipeline - AD HOC NEWS
Merck & Co., Inc. (MRK) is a trending stock: Facts to know before betting on it - MSN
Merck & Co. opens the week with analyst focus, shares on NYSE - AD HOC NEWS
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):